AstraZeneca's Financial Growth in Q1 2025

AstraZeneca PLC has kicked off the fiscal year 2025 with impressive financial results, announcing a 7% annual increase in revenue, reaching $13.6 billion. This growth is even more significant at a constant exchange rate (CER), showing a 10% rise.

Product Sales and Profit Margins

The company's product sales have seen a 6% increase year-on-year, or 9% at CER, totaling $12.9 billion. Additionally, the core operating profit has grown by 12%, with reported earnings per share (EPS) soaring by 35% (32% at CER) to $1.88.

Future Outlook

Looking ahead, AstraZeneca forecasts a high single-digit percentage increase in total revenue for 2025, alongside a low double-digit growth in core EPS. CEO Pascal Soriot expressed confidence in the company's strategy, emphasizing its commitment to growth in the US and its global manufacturing capabilities. "We are on track to achieve our ambitious goal of $80 billion in Total Revenue by 2030," Soriot stated.